Company intelligence / Profile preview

Shanghai Hanmai Biomedical Technology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Hanmai Biomedical is a Shanghai-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics. The company leverages advanced structure-based drug design (SBDD) and medicinal chemistry platforms to target high-value biological pathways in oncology and immunology. Hanmai aims to address unmet medical needs by developing next-generation inhibitors with improved selectivity and potency. Currently, the company's portfolio is in the early stages of development, with several programs undergoing lead optimization and pre-clinical evaluation.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

M-02

Unknown

Beyond the preview

Go deeper on Shanghai Hanmai Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Hanmai Biomedical Technology.

Explore the full profile